key: cord-1055586-0df6niew
authors: Zaffina, Salvatore; Alteri, Claudia; Ruggiero, Alessandra; Cotugno, Nicola; Vinci, Maria Rosaria; Camisa, Vincenzo; Santoro, Anna Paola; Brugaletta, Rita; Deriu, Gloria; Mortari, Eva Piano; Salinas, Ane Fernandez; Russo, Cristina; Ranno, Stefania; Coltella, Luana; Colagrossi, Luna; Porzio, Ottavia; Muda, Andrea Onetti; Raponi, Massimiliano; Ciofi degli Atti, Marta; Rizzo, Caterina; Villani, Alberto; Rossi, Paolo; Palma, Paolo; Carsetti, Rita; Perno, Carlo Federico
title: Induction of Immune Response After SARS-CoV-2 mRNA BNT162b2 Vaccination in Healthcare Workers
date: 2021-05-19
journal: J Virus Erad
DOI: 10.1016/j.jve.2021.100046
sha: 4a941e5a409407adbcd5ebb82c9185c4ecf0563d
doc_id: 1055586
cord_uid: 0df6niew

nan

A two-dose regimen of the BNT162b2 mRNA COVID-19 vaccine (30 μg per dose, given 21 days 34 apart) was found to be safe and 95% effective against COVID-19, with mild to moderate side-35 effects gone within a few days in recent published clinical trials. [1] [2] Due to the high level of 36 protection against COVID-19 critical needed in the current pandemic, the European Medicines 37 Agency (EMA) authorised its use in the EU on December 21, 2020. 38

Recent real-world data have shown a 30-50% reduction of COVID-19 cases after the first vaccine 39 dose. [3] [4] This increased to 75% after the second dose with an 85% drop in COVID-19 40 hospitalizations. 4 Serum samples were available before the first dose, and at 7, 21, and 28 days afterwards. All 46

HCWs had a negative SARS-CoV-2 status by molecular (Allplex2019-nCov, Seegene) and 47 antibody assays (Elecsys®Anti-SARS-CoV-2, Roche). Presence and titers of anti-S in serum 

BNT162b2 mRNA Covid-19 Vaccine

Safety and Immunogenicity of Two RNA-Based 121

Covid-19 Vaccine Candidates

The Effectiveness of the First Dose of BNT162b2

Vaccine in Reducing SARS-CoV-2 Infection: Real-World Evidence. Available at SSRN: 124

Early rate reductions of SARS-CoV-126 2 infection and COVID-19 in BNT162b2 vaccine recipients

Effectiveness of First Dose of COVID-19

Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 129 5.4 Million People

antibody and TH1 T cell responses

Longitudinal isolation of potent near-germline SARS-145

CoV-2-neutralizing antibodies from COVID-19 patients

Durability of Responses after SARS-CoV-2 147 mRNA-1273 Vaccination

Impact of age, ethnicity, sex and prior infection 149 status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 150 vaccine: real-world evidence from healthcare workers

COVID-19 and Older Adults: What We 153

Detection and quantification of SARS-CoV-2 by 155 droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected 156 COVID-19 patients

Association Between Vaccination With BNT162b2 and 158 Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care 159

Initial report of decreased SARS-CoV-2 viral load after 161 Declaration of interests ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work